The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab-Reference-Cited by-同舟云学术

The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab

Published:2020-10-12 Issue:4 Volume:31 Page:919-923
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Ito Satoshi¹,Sakai Shunsuke¹²,Kurosawa Yoichi¹²,Kobayashi Daisuke¹²,Okabayashi Ryo¹,Abe Asami¹,Otani Hiroshi¹,Nakazono Kiyoshi¹,Murasawa Akira¹,Narita Ichiei²,Ishikawa Hajime¹

Affiliation:

1. Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

2. Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2020.1823551

Reference8 articles.

1. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

2. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients

3. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial

4. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

5. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values